345 related articles for article (PubMed ID: 12051548)
1. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.
Vahle JL; Sato M; Long GG; Young JK; Francis PC; Engelhardt JA; Westmore MS; Linda Y; Nold JB
Toxicol Pathol; 2002; 30(3):312-21. PubMed ID: 12051548
[TBL] [Abstract][Full Text] [Related]
2. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats.
Jolette J; Wilker CE; Smith SY; Doyle N; Hardisty JF; Metcalfe AJ; Marriott TB; Fox J; Wells DS
Toxicol Pathol; 2006; 34(7):929-40. PubMed ID: 17178693
[TBL] [Abstract][Full Text] [Related]
3. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893.
Stewart AF; Cain RL; Burr DB; Jacob D; Turner CH; Hock JM
J Bone Miner Res; 2000 Aug; 15(8):1517-25. PubMed ID: 10934650
[TBL] [Abstract][Full Text] [Related]
4. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
Jolette J; Attalla B; Varela A; Long GG; Mellal N; Trimm S; Smith SY; Ominsky MS; Hattersley G
Regul Toxicol Pharmacol; 2017 Jun; 86():356-365. PubMed ID: 28389324
[TBL] [Abstract][Full Text] [Related]
5. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits.
Hirano T; Burr DB; Turner CH; Sato M; Cain RL; Hock JM
J Bone Miner Res; 1999 Apr; 14(4):536-45. PubMed ID: 10234574
[TBL] [Abstract][Full Text] [Related]
6. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats.
Schmitt CP; Hessing S; Oh J; Weber L; Ochlich P; Mehls O
Kidney Int; 2000 Apr; 57(4):1484-92. PubMed ID: 10760084
[TBL] [Abstract][Full Text] [Related]
7. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.
Vahle JL; Long GG; Sandusky G; Westmore M; Ma YL; Sato M
Toxicol Pathol; 2004; 32(4):426-38. PubMed ID: 15204966
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic agents for disorders of bone and calcium metabolism--Parathyroid hormone in weekly subcutaneous injection].
Uzawa T
Clin Calcium; 2007 Jan; 17(1):56-62. PubMed ID: 17211094
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone.
Pfeilschifter J; Laukhuf F; Müller-Beckmann B; Blum WF; Pfister T; Ziegler R
J Clin Invest; 1995 Aug; 96(2):767-74. PubMed ID: 7635970
[TBL] [Abstract][Full Text] [Related]
10. Study on preparation and activity of a novel recombinant human parathyroid hormone(1-34) analog with N-terminal Pro-Pro extension.
Chunxiao W; Jingjing L; Yire X; Min D; Zhaohui W; Gaofu Q; Xiangchun S; Xuejun W; Jie W; Taiming L
Regul Pept; 2007 Jun; 141(1-3):35-43. PubMed ID: 17300845
[TBL] [Abstract][Full Text] [Related]
11. Sequential treatment with basic fibroblast growth factor and parathyroid hormone restores lost cancellous bone mass and strength in the proximal tibia of aged ovariectomized rats.
Wronski TJ; Ratkus AM; Thomsen JS; Vulcan Q; Mosekilde L
J Bone Miner Res; 2001 Aug; 16(8):1399-407. PubMed ID: 11499862
[TBL] [Abstract][Full Text] [Related]
12. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.
Kostenuik PJ; Ferrari S; Pierroz D; Bouxsein M; Morony S; Warmington KS; Adamu S; Geng Z; Grisanti M; Shalhoub V; Martin S; Biddlecome G; Shimamoto G; Boone T; Shen V; Lacey D
J Bone Miner Res; 2007 Oct; 22(10):1534-47. PubMed ID: 17576164
[TBL] [Abstract][Full Text] [Related]
13. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
[TBL] [Abstract][Full Text] [Related]
14. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing.
Nakazawa T; Nakajima A; Shiomi K; Moriya H; Einhorn TA; Yamazaki M
Bone; 2005 Nov; 37(5):711-9. PubMed ID: 16143574
[TBL] [Abstract][Full Text] [Related]
15. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
16. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
Ma Y; Jee WS; Chen Y; Gasser J; Ke HZ; Li XJ; Kimmel DB
J Bone Miner Res; 1995 Nov; 10(11):1726-34. PubMed ID: 8592950
[TBL] [Abstract][Full Text] [Related]
17. Osteosarcoma risk in rats using PTH 1-34.
Barbehenn EK; Lurie P; Wolfe SM
Trends Endocrinol Metab; 2001 Nov; 12(9):383. PubMed ID: 11595538
[No Abstract] [Full Text] [Related]
18. Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase.
Rixon RH; Whitfield JF; Gagnon L; Isaacs RJ; Maclean S; Chakravarthy B; Durkin JP; Neugebauer W; Ross V; Sung W
J Bone Miner Res; 1994 Aug; 9(8):1179-89. PubMed ID: 7976500
[TBL] [Abstract][Full Text] [Related]
19. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat.
Zhou H; Shen V; Dempster DW; Lindsay R
J Bone Miner Res; 2001 Jul; 16(7):1300-7. PubMed ID: 11450706
[TBL] [Abstract][Full Text] [Related]
20. Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys.
Brommage R; Hotchkiss CE; Lees CJ; Stancill MW; Hock JM; Jerome CP
J Clin Endocrinol Metab; 1999 Oct; 84(10):3757-63. PubMed ID: 10523026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
